379 related articles for article (PubMed ID: 34576262)
1. Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.
Alsherbiny MA; Bhuyan DJ; Low MN; Chang D; Li CG
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576262
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells.
Alsherbiny MA; Bhuyan DJ; Radwan I; Chang D; Li CG
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360606
[TBL] [Abstract][Full Text] [Related]
3. CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer.
Fraguas-Sánchez AI; Fernández-Carballido A; Simancas-Herbada R; Martin-Sabroso C; Torres-Suárez AI
Int J Pharm; 2020 Jan; 574():118916. PubMed ID: 31811927
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
5. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
[TBL] [Abstract][Full Text] [Related]
6. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Konecny G; Untch M; Slamon D; Beryt M; Kahlert S; Felber M; Langer E; Lude S; Hepp H; Pegram M
Breast Cancer Res Treat; 2001 Jun; 67(3):223-33. PubMed ID: 11561768
[TBL] [Abstract][Full Text] [Related]
7. In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Budman DR; Calabro A
Breast Cancer Res Treat; 2002 Jul; 74(1):41-6. PubMed ID: 12150451
[TBL] [Abstract][Full Text] [Related]
8. Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines.
Hahm HA; Dunn VR; Butash KA; Deveraux WL; Woster PM; Casero RA; Davidson NE
Clin Cancer Res; 2001 Feb; 7(2):391-9. PubMed ID: 11234895
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.
Tun JO; Salvador-Reyes LA; Velarde MC; Saito N; Suwanborirux K; Concepcion GP
Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31527453
[TBL] [Abstract][Full Text] [Related]
10. Codelivery of Paclitaxel and Everolimus at the Optimal Synergistic Ratio: A Promising Solution for the Treatment of Breast Cancer.
Houdaihed L; Evans JC; Allen C
Mol Pharm; 2018 Sep; 15(9):3672-3681. PubMed ID: 29863881
[TBL] [Abstract][Full Text] [Related]
11. Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles.
Fraguas-Sánchez AI; Fernández-Carballido A; Delie F; Cohen M; Martin-Sabroso C; Mezzanzanica D; Figini M; Satta A; Torres-Suárez AI
Eur J Pharm Biopharm; 2020 Sep; 154():246-258. PubMed ID: 32682943
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
13. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.
Ward SJ; McAllister SD; Kawamura R; Murase R; Neelakantan H; Walker EA
Br J Pharmacol; 2014 Feb; 171(3):636-45. PubMed ID: 24117398
[TBL] [Abstract][Full Text] [Related]
15. In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio.
Baabur-Cohen H; Vossen LI; Krüger HR; Eldar-Boock A; Yeini E; Landa-Rouben N; Tiram G; Wedepohl S; Markovsky E; Leor J; Calderón M; Satchi-Fainaro R
J Control Release; 2017 Jul; 257():118-131. PubMed ID: 27374630
[TBL] [Abstract][Full Text] [Related]
16. The synergistic anticancer effect of CBD and DOX in osteosarcoma.
Li J; Jiang W; Shan W; Luo A; Qu G; Zhang J; Luo X; Xia J
Clin Transl Oncol; 2023 Aug; 25(8):2408-2418. PubMed ID: 36848028
[TBL] [Abstract][Full Text] [Related]
17. Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Li W; Zhai B; Zhi H; Li Y; Jia L; Ding C; Zhang B; You W
Tumour Biol; 2014 Sep; 35(9):8883-91. PubMed ID: 24894670
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab and chemotherapeutics: drug interactions and synergies.
Pegram MD; Lopez A; Konecny G; Slamon DJ
Semin Oncol; 2000 Dec; 27(6 Suppl 11):21-5; discussion 92-100. PubMed ID: 11236023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
